Drugs / CD3/CD19 negative hematopoietic stem cells
CD3/CD19 negative hematopoietic stem cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03500731 | Apr 2018 → Dec 2027 expected | chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis | Paul Szabolcs | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD3/CD19 negative hematopoietic stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03500731 ↗ |
| Modality | Cell therapy | “Biological: CD3/CD19 negative hematopoietic stem cells” NCT03500731 ↗ |